McLean C S, Churcher M J, Meinke J, Smith G L, Higgins G, Stanley M, Minson A C
Department of Pathology, University of Cambridge.
J Clin Pathol. 1990 Jun;43(6):488-92. doi: 10.1136/jcp.43.6.488.
A monoclonal antibody was raised against the major capsid protein L1 of human papillomavirus type 16, using a recombinant vaccinia virus that expresses the L1 protein, as a target for screening. This antibody, designated CAMVIR-1, reacted with a 56 kilodalton protein in cells infected with L1-vaccinia virus, and the protein was present in a predominantly nuclear location. The antibody also detects the HPV-16 L1 antigen in formalin fixed, paraffin wax embedded biopsy specimens and on routine cervical smears. The antibody reacts strongly and consistently with biopsy specimens containing HPV-16 or HPV-33, but very weak reactions were occasionally observed with biopsy specimens or smears containing HPV-6 or HPV-11. The potential advantages of using a vaccinia recombinant are (i) the target protein is synthesised in a eukoryotic cell so that its "processing" and location are normal; (ii) cells infected with vaccinia recombinants can be subjected to various fixing procedures similar to those used for routine clinical material. This greatly increases the probability that an identified antibody will be useful in a clinical setting.
以表达人乳头瘤病毒16型主要衣壳蛋白L1的重组痘苗病毒作为筛选靶标，制备了抗该蛋白的单克隆抗体。这种名为CAMVIR-1的抗体与感染L1-痘苗病毒的细胞中的一种56千道尔顿的蛋白发生反应，该蛋白主要位于细胞核中。该抗体还能在福尔马林固定、石蜡包埋的活检标本以及常规宫颈涂片上检测到HPV-16 L1抗原。该抗体与含有HPV-16或HPV-33的活检标本反应强烈且一致，但偶尔也会观察到与含有HPV-6或HPV-11的活检标本或涂片的反应非常微弱。使用痘苗重组体的潜在优势在于：（i）靶蛋白在真核细胞中合成，因此其“加工”和定位正常；（ii）感染痘苗重组体的细胞可以进行各种类似于常规临床材料所用的固定程序。这大大增加了所鉴定抗体在临床环境中有用的可能性。
